Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire

Inclusion Criteria: * Women aged 21 or older, who have signed informed concent, with a regular menstrual cycle (STRAW stages -5 to -3 (see Annex 7)). * The level of follicle-stimulating hormone (FSH) is not more than 25 milli-International unit per ml (mIU/ml) according to the screening values. * Decrease or loss of sexual desire (ICD-10 code: F-52.0) corresponding to the hypoactive sexual desire disorder (HSDD) diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM4), criteria. * Current HSDD episode lasting not less than 24 weeks. * Patients with secondary female sexual arousal disorder (FSAD) and/or female orgasmic disorder (FOD) will be eligible only if the HSDD developed before the FSAD and/or FOD and the HSDD has a more significant impact on the patient's quality of life. * Not less than 15 scores according to the FSDS-R (Distress) Total Score. * Stable monogamous relationship with one sexually active male sexual partner lasting at least a year. The partner is physically available not less than 50% of time during a month. * Consent to attempt to have a sexual intercourse at least twice a month, if she has a desire. * Consent to complete a diary every day during the screening period and assessment of the baseline state (in this period diary records must cover ≥80% days), during the therapy and subsequent follow-up. * Consent to use adequate methods of contraception throughout the study. Exclusion Criteria: * Any prohibited treat…